Réglementation et droit · 09/12/19971 min de lecture
Prospective Grant of Exclusive License: Therapeutic Uses of Blood Vessel Growth Promoting Peptides Including Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (FGF) for Cardiovascular Disease and Conditions Such as Myocardial Ischemia
Traduction automatique locale · Langue originale de la source
Résumé
This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a domestic exclusive license to practice the inventions embodied in the patent referred to below to Collateral Therapeutics of San Diego, California. The patent rights in these inventions have been assigned to the government of the United States of America. The patent to be licensed is: ``Method To Foster Myocardial Blood Vessel Growth And Improve Blood Flow To The Heart'', U.S. Patent Application Serial No. 07/799,830 filed November 27, 1991, which issued as U.S. Patent No. 5,244,460 on September 14, 1993.